Best of heart failure

71 3. Solomon SD, Dobson J, Pocock S, S Granger CB, Yusuf S, Swedberg K, Y Pfeffer MA, for the Candesartan in Hea Reduction in Mortality and morbidity (2007) Influence of nonfatal hospitaliz subsequent mortality in patients wit Circulation 116(13):1482 – 1487 4. Ramirez A, Abelmann WH (1974) C NEJM 290(9):499 – 501 5. Peacock WF, Braunwald E, Abraham Christenson R, Collins S, Diercks D, Kellerman A, Gheorghiade M, Kirk D, BM, O'Connor C, Pang P, Shah M, Sopk A, Teerlink J (2010) National Heart, L working group on emergency departme heart failure: research challenges and op 343 – 351 6. Hamo CE, Butler J, Gheorghiade M, bumpy road to drug development for Heart J Supp 18(Supplement G):G19 – G 7. Gheorghiade M, Braunwald E (2011) A assessment and management of acute JAMA 305:1702 – 1703 8. Ponikowski P, Voors AA, Anker SD et al the diagnosis and treatment of acute and task force for the diagnosis and treatment failure of the European Society of Car with the special contribution of the Hea the ESC. Eur Heart J 37(27):2129 – 2200 9. Cleland JG, Pennel D, Ray S, Murray G, Coats A, Lahiri A (1999) The Carvedil Ischemia Trial: Marker of Success (CHRI 1:191 – 196 10. Cleland JG, Pennell DJ, Ray SG, Co Murray GD, Mule JD, Vered Z, Lahiri reversible ischaemia trial: marker of suc half of the CHRISTMAS (Carvedilol Ischaemia Trial: Maker of Success Myocardial viability as a determinant o sponse to carvedilol in patients with he trial): randomised controlled trial. Lancet 11. Greene SJ, Vaduganathan M, Gheorghia road to recovery: therapeutic and clinical functional viable myocardium in heart fai fraction. Eur J Heart Fail 19(7):870 – 872 12. Adamsom PB, Magalski A, Braunschwei right ventricular hemodynamics in heart measurements derived form an implanta Am Coll Cardiol 41:565 – 571 13. Zile MR, Bennett TD, St John Sutton from chronic compensated to acute dec pathophysiological insights obtained fro of intracardiac pressures. Circulation 118 14. Stevenson LW, Perloff JK (1989) The lim signs for estimating hemodynamics in ch 261:884 – 888 15. Gheorghiade M, Follath F, Ponikowski Cleland JG, Dickstein K, Drazner MH, Jondeau G, Sendon JL, Mebazaa A, Met PS, Seferovic P, Stevenson LW, van Anker SD, Rhodes A, McMurray J, Society of Cardiology, European So Medicine (2010) Assessing and grading failure. Eur J Heart Fail 12(5):423 – 433 16. Ambrosy AP, Khan H, Udelson JE, Ment SJ, Vaduganathan M, Subacuis HP, Ko Heart Fail Rev (2018) 23:597 – 607 recommended to be in reach the target 97/10 should not be given c to risk for angioedema, stopped for 36 h bef patients with eGFR < impairment, the starti daily and ARNI is not hepatic impairment [ 3 With the results of t ommendations have b HF Guidelines. First, ACE inhibitors or an strategy of RAS inhibit or ARB or ARNI. T strategy of i hibition of evidence: A), or A (level of evidence: B – beta-blockers and aldo is ecommended for p morbidity and mortalit In the 2017 Focuse with chronic symptom tolerate an ACE inhibit recommended to furth 36 •• ]. In those patie switched to ARNI fro to note that ARNI sho with ACE inhibitors or inhibitor due to angio should not be administ edem [ 1 •• ]. In the stu inhibition, blacks and angioedema [ 35 ]. It is be educated about rec ma and to lert health scription of ACE inhi In a phase II trial i served ejection fractio reater extent than di tolerat d [ 39 ]. The eff compensated HF, in a IV symptoms, or in p time and is bei g te te Ivabradine Ivabradine is a specifi chann l. If io ch n el in spontaneously activ node, the AV node, an is a mixed Na/K curre at voltages in the dia 39 Page 4 of 9 30. Goonewardena SN, Gemignani A, Ronan A, Vasaiwala S, Blair J, Brennan JM, Shah DP, Spencer KT (2008) Comparison of hand- carried ultrasound assessment of the inferior vena cava and N- terminal pro-brain natriuretic peptide for predicting readmission after hospitalization for acute decompensated heart failure. JACC Cardiovasc Imaging 1(5):595 – 601 31. Van De Water JM, Miller TW (2003) Impedance cardiography: the next vital sign technology? Chest 123(6):2028 – 2033 32. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Masoudi FA, McBride PE, McMurray JJV, Mitchell JE, Peterson PN, Riegel B, Sam F, Stevenson LW, Wilson Tang WH, Tsai EJ, Bruce L (2013) Wilkoff. 2013 ACCF/ AHA guideline for the management of heart failure. Circulation 128:e240 – e327 33. Testani JM, Chen J, McCauley BD et al (2010) Potential ef- fects of aggressive decongestion during the treatment of de- compensated heart failure on renal function and survival. Circulation 122:265 – 272 34. Greene SJ, Gheorghiade M, Vaduganathan M, Ambrosy AP, Mentz RJ, Subacius H, Maggioni AP, Nodari S, Konstam MA, Butler J, Filippatos G, on behalf of the EVEREST Trial investigators (2013) EVEREST trial investigators: Haemoconcentration, renal function, and post-discharge outcomes among patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial. Eur J Heart Fail 15:1401 – 1411 35. Testani JM, Kimmel SE, Dries DL, Coca SG (2011) Prognostic importance of early worsening renal function after initiation of angiotensin-converting enzyme inhibitor therapy in patients with cardiac dysfunction. Circ Heart Fail 4(6):685 – 691 36. Rossignol P, Cleland JG, Bhandari S et al (2012) Determinants and consequences of renal function variations with aldosterone blocker therapy in heart failure patients after myocardial infarction: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study. Circulation 125:271 – 279 37. Golwala HB et al (2013) Use of hydralazineisosorbide dinitrate combination in African American and other race/ethnic group pa- tients with heart failure and reduced left ventricular ejection frac- tion. J Am Heart Assoc 2:e000214 38. Gheorghiade M, Braunwald E (2009) Reconsidering the role for digoxin in the management of acute heart failure syndromes. JAMA 302:2146 – 2147 39. The Digitalis Investigation Group (1997) The effect of digoxin on mortality and morbidity in patients with heart failure. NEJM 336: 525 – 533 40. Albert NM, Yancy CW, Liang L, Zhao X, Hernandez AF, Peterson ED, Cannon CP, Fonarow GC (2009) Use of aldosterone antago- nists in heart failure. JAMA 302:1658 – 1665 41. Schrier RW, Gheorghiade M (2011) Challenge of rehospitalizations for heart failure: potential of natriuretic doses of mineralocorticoid receptor antagonists. Am Heart J 161:221 – 223 42. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J (1999) The effect of spironolactone on mor- bidity and mortality in patients with severe heart failure. NEJM 341:709 – 717 43. Gines P, Schrier RW (2009) Renal failure in cirrhosis. NEJM 361: 1279 – 1290 44. Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B, Clausell N, Desai AS, Diaz R, Fleg JL, Gordeev I, Harty B, Heitner JF, Kenwood CT, Lewis EF, O'Meara E, Probstfield JL, Shaburishvili T, Shah SJ, Solomon SD, Sweitzer NK, Yang S, McKinlay S, TOPCAT Investigators (2014) Spironolactone for heart failure with preserved ejection fraction. NEJM 370(15): 1383 – 1392 45. Bikdeli B, Strait KM, Dharmarajan K, Partovian C, Coca SG, Kim N, Li SX, Testani JM, Khan U, Krumholz HM (2013) Dominance of furosemide for loop diuretic therapy in heart failuretime to revisit the alternatives? JACC 61(14):1549 – 1550 46. Müller K, Gamba G, Jaquet F, Hess B (2003) Torasemide vs. furo- semide in primary care patients with chronic heart ailure NYHA II to IV — efficacy and quality of life. Eur J Heart Fail 5(6):793 – 801 47. Kasama S, Toyama T, Hatori T, Sumino H, Kumakura H, Takayama Y, Ichikawa S, Suzuki T, Kurabayashi M (2006) Effects of torasemide on cardiac sympathetic nerve activity and left ventricular remodelling in patients with congestive hea t failure. Heart 92(10):1434 – 1440 48. Vargo DL, Kramer WG, Black PK, Smith WB, Serpas T, Brater DC (1995) Bioavailability, pharmacokinetics, and pharmacodynamics of torsemide and furosemide in patients with congestive heart fail- ure. Clin Pharmacol Ther 57(6):601 – 609 49. Buggey J, Mentz RJ, Pitt B, Eisenstein EL, Anstrom KJ, Velazquez EJ, O'Connor CM (2015) A reappraisal of loop diuretic choice in heart failure patients. Am Heart J 1 9(3):323 – 333 50. Bleske BE, Welage LS, Kramer WG, Nickl s JM (1998) Pharmacokinetics of torsemide in patients with decompensated and compensated congestive heart failure. J Clin Pha macol 38(8):708 – 714 51. Elhassan EA, Schrier RW. Disorders of extracellular volume. Compr Clin Nephrol (4e). 2010. 80 – 93. rint 52. Ellison DH (1991) The physiologic basis of iuretic y ergism: its role in treating diuretic resistance. Ann Int Med 114(10):886 – 894 53. Swedberg K, Komajda M, Bohm M et l (2010) Ivabradin and outcomes in chronic heart failure (SHIFT): a randomized placebo- controlled study. Lancet 376(9744):875 – 885 54. Segura LM (2011) Dual-acting angiotensin receptor-nepri ysin in- hibition. Curr Hypertens Rep 13:74 – 78 55. McMurray JJV, Packer M, Desai AS, Gong J, Lefk witz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR, PARADIGM-HF Investigators and Committ es (2014) Angiotensin-neprilysin inhibition versus enal pril in heart failure. N Engl J Med 371:993 – 1004 56. Xie W, Zheng F, Song X, Zhong B, Yan L (2016) R nin- angiotensin-aldosterone system blockers for heart failure with re- duced ejection fraction or left ventricular d sfunct on: network me- ta-analysis. Int J Cardiol 205:65 – 71 57. Desai AS, Claggett BL, Packer M, Zile MR, Rouleau JL, Swedberg K, Shi V, Lefkowitz M, Starling R, Te rlink , McMurray J, Solomon SD, PARADIGM-HF Investigators (2016) Influence of sacubitril/valsartan (LCZ696) on 30-day readmiss on after heart failure hospitalization. J Am Coll Cardiol 68(3):241 – 248 58. Li PK, ChowKM, tal V d LMWe (2017) Changes in the worldwide epidemiology of peritoneal dialysis. Nat Rev Neph ol 13(2):90 – 103 59. Bart BA, Goldsmith SR, Lee KL et al (2012) Ultrafilt ation in decompensated heart failure with cardiorenal syndrome. NEJM 367:2296 – 2304 60. Costanzo MR, Negoianu D, Jaski BE, Bart BA, Heywood JT, Anand IS, Smelser JM, Kaneshige AM, C msky DB, Adl r ED, Haas GJ, Watts JA, Nabut JL, Schollmeye MP, Fonarow G (2016) Aquapheresis versus intravenous diuretics and hospitaliza- tions for heart failure. JACC: Heart Failure 4(2):95 – 105 61. Mehrotra R, Kathuria P Place of peritoneal dialysis in the manage- ment of treatment-resistant congestive heart fa lur . Kidney Int Suppl 103:S67 – S71 62. Cnossen TT, Kooman JP, Konings CJ (2010) Peritoneal ialysis in patients with primary cardiac failure complicated by renal failure. Blood Purif 20:146 – 152 63. Nunez J, Gonazalez M, Minana G et al (2012) C ntinuous ambu- latory peritoneal dialysis as a therapeutic alt rnative in patie t with advanced congestive heart failure. Eur J Hea t Fail 14:540 – 548 64. Chioncel O, Lainscak M, Seferovic PM, Anker SD, Crespo-Leiro MG, Harjola VP, Parissis J, Laroche C, Piepoli MF, Fonseca C, Mebazaa A, Lund L, Ambrosio GA, Coats AJ, Ferrari R, 606 Heart Fail Rev (2018) 23:597 – 607